Cigna: Pandemic Led to Fewer New Scripts, Better Adherence
April
26
In its 2020 Drug Trend Report, Cigna Corp. division Evernorth said total drug costs rose 4% for its commercial plans, including both utilization and unit costs. The COVID-19 pandemic led to an across-the-board decline in the percentage of new medication users as well as improved adherence among people taking medications for chronic conditions. Among the top 15 therapy classes ranked by per-member per-year spend for the commercial plans, inflammatory conditions remained the top of the list, at $241.34 PMPY average spending, followed by diabetes at $145.24.
SOURCE: Evernorth. Visit https://www.evernorth.com/drug-trend-report.
Related Posts
September
21
McClellan: IRA Price Negotiations May Have Broader Impact Beyond Drugs on List
Read More
September
21
FDA Approves First Multiple Sclerosis Biosimilar, Sandoz’s Tyruko
Read More
September
21
Now That Humira Biosimilars Have Launched, What Are Lessons Learned for Stelara Biosimilars?
Read More
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile